Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Myelodysplastic Syndrome With Excess Blasts-2: early-phase trial registry
2 of 3 indexed Myelodysplastic Syndrome With Excess Blasts-2 trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 2 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Myelodysplastic Syndrome With Excess Blasts-2: 3 US clinical trials tracked, 2 recruiting.
Myelodysplastic Syndrome With Excess Blasts-2 is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Aptose Biosciences, running 1 of these trials.
Enrollment posture brief
Registry condition myelodysplastic-syndrome-with-excess-blasts-2
OPEN 2 | RECR 67% | LATE 0 | EARLY 3 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Acute Hypoxemic Respiratory Failure (67% recruiting · 6 trials)
Myelodysplastic Syndrome With Excess Blasts-2 lists 2 open slots (67% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Myelodysplastic Syndrome With Excess Blasts-2 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Myelodysplastic Syndrome With Excess Blasts-2 is recruiting above its size-band peers.
2 of 3 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Aptose Biosciences
NCT03850574
BXCL701 Phase 1 R/R Acute Myeloid Leukemia or Myelodysplastic Syndrome
Eric Stephen Winer, MD
NCT05703542
Hu8F4 in Treating Patients With Advanced Hematologic Malignancies
M.D. Anderson Cancer Center
NCT02530034
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Myelodysplastic Syndrome With Excess Blasts-2 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Myelodysplastic Syndrome With Excess Blasts-2 trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Myelodysplastic Syndrome With Excess Blasts-2 page
3 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Myelodysplastic Syndrome With Excess Blasts-2 trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Aptose Biosciences sponsors the most Myelodysplastic Syndrome With Excess Blasts-2 trials on record, review their full trial history before evaluating a specific study. See Aptose Biosciences's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Myelodysplastic Syndrome With Excess Blasts-2 condition card totals 3 registered trials; most-linked intervention Anti-PR1/HLA-A2 Monoclonal Antibody Hu8F4; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.